Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials

The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multicenter, double-blind, placebo-controlled trials. Adults (study 1, n=383; study 2, n=390) meeting DSM-IV-TR BED criteria were randomized (1:1) to placebo or LDX (50 or 70 m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuropsychopharmacology
Päätekijät: McElroy, Susan L, Hudson, James, Ferreira-Cornwell, M Celeste, Radewonuk, Jana, Whitaker, Timothy, Gasior, Maria
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4793109/
https://ncbi.nlm.nih.gov/pubmed/26346638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2015.275
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia